AE Management for CAR-T Therapy: Expert Insights and Perspectives

Opinion
Video

Samer Al'Hadidi, MD, provides a comprehensive overview of adverse event management practices for patients with multiple myeloma who receive CAR T-cell therapy.

Recent Videos
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
4 experts in this video
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
4 experts in this video
Related Content